Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.57 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.57 |
| ▸ | AHCY | P23526 | 1/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358012 | 1.00 | POLB (0.58) | POLBENPP1P2RY1AHCYEHMT1 | |
| SCHEMBL5369306 | 0.96 | POLB (0.59) | POLBENPP1P2RY1AHCYEHMT1 | |
| SCHEMBL5359628 | 0.90 | HIF1A (0.48) | POLBENPP1P2RY1 | |
| SCHEMBL22875428 | 0.90 | AHCY (0.47) | POLBENPP1P2RY1AHCYEHMT1 | |
| SCHEMBL2691352 | 0.88 | POLB (0.62) | POLBENPP1P2RY1AHCYPRKACA | |
| SCHEMBL8058699 | 0.86 | POLB (0.64) | POLBENPP1P2RY1AHCY | |
| SCHEMBL1889395 | 0.86 | POLB (0.64) | POLBENPP1P2RY1AHCY | |
| SCHEMBL8623380 | 0.85 | POLB (0.65) | POLBENPP1P2RY1AHCY | |
| SCHEMBL3259692 | 0.85 | POLB (0.65) | POLBENPP1P2RY1AHCY | |
| SCHEMBL7133529 | 0.85 | POLB (0.59) | POLBENPP1P2RY1AHCYPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-30 | — | — | US | disclosed |
| US-6743782-B1 | ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY | WELLSTAT THERAPEUTICS CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-6020320-A | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 2000-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | UNG, OGG1, NQO1 | POLB 46/4885ENPP1 122/4885P2RY1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.